MetLife Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.3M | Sell |
22,880
-687
| -3% | -$468K | 0.06% | 290 |
|
|
2026
Q1 | $18.2M | Sell |
23,567
-607
| -3% | -$465K | 0.09% | 192 |
|
|
2025
Q4 | $18.7M | Sell |
24,174
-1,144
| -5% | -$777K | 0.09% | 181 |
|
|
2025
Q3 | $14.2M | Sell |
25,318
-1,152
| -4% | -$651K | 0.07% | 266 |
|
|
2025
Q2 | $13.9M | Sell |
26,470
-1,227
| -4% | -$685K | 0.08% | 226 |
|
|
2025
Q1 | $17.6M | Sell |
27,697
-543
| -2% | -$373K | 0.09% | 181 |
|
|
2024
Q4 | $20.1M | Buy |
28,240
+273
| +1% | +$229K | 0.11% | 139 |
|
|
2024
Q3 | $29.4M | Sell |
27,967
-708
| -2% | -$788K | 0.17% | 96 |
|
|
2024
Q2 | $30.1M | Buy |
28,675
+3,708
| +15% | +$3.59M | 0.18% | 90 |
|
|
2024
Q1 | $24M | Sell |
24,967
-1,239
| -5% | -$1.18M | 0.16% | 104 |
|
|
2023
Q4 | $23M | Sell |
26,206
-429
| -2% | -$353K | 0.17% | 103 |
|
|
2023
Q3 | $21.9M | Sell |
26,635
-961
| -3% | -$755K | 0.17% | 99 |
|
|
2023
Q2 | $19.8M | Sell |
27,596
-675
| -2% | -$520K | 0.14% | 113 |
|
|
2023
Q1 | $23.2M | Sell |
28,271
-230
| -0.8% | -$173K | 0.17% | 101 |
|
|
2022
Q4 | $20.6M | Sell |
28,501
-509
| -2% | -$376K | 0.16% | 110 |
|
|
2022
Q3 | $20M | Sell |
29,010
-623
| -2% | -$392K | 0.17% | 99 |
|
|
2022
Q2 | $17.5M | Buy |
29,633
+196
| +0.7% | +$127K | 0.14% | 126 |
|
|
2022
Q1 | $20.6M | Buy |
29,437
+6,078
| +26% | +$3.85M | 0.13% | 119 |
|
|
2021
Q4 | $14.8M | Sell |
23,359
-381
| -2% | -$234K | 0.12% | 131 |
|
|
2021
Q3 | $14.4M | Sell |
23,740
-533
| -2% | -$331K | 0.13% | 132 |
|
|
2021
Q2 | $13.6M | Sell |
24,273
-817
| -3% | -$414K | 0.12% | 140 |
|
|
2021
Q1 | $11.9M | Sell |
25,090
-376
| -1% | -$183K | 0.11% | 157 |
|
|
2020
Q4 | $12.3M | Sell |
25,466
-1,041
| -4% | -$562K | 0.12% | 148 |
|
|
2020
Q3 | $14.8M | Buy |
26,507
+126
| +0.5% | +$76.4K | 0.16% | 110 |
|
|
2020
Q2 | $16.5M | Buy |
26,381
+5,790
| +28% | +$3.29M | 0.19% | 98 |
|
|
2020
Q1 | $10.1M | Sell |
20,591
-630
| -3% | -$260K | 0.14% | 141 |
|
|
2019
Q4 | $7.97M | Sell |
21,221
-525
| -2% | -$177K | 0.08% | 214 |
|
|
2019
Q3 | $6.03M | Buy |
21,746
+69
| +0.3% | +$20.4K | 0.07% | 274 |
|
|
2019
Q2 | $6.78M | Sell |
21,677
-45,172
| -68% | -$15M | 0.07% | 245 |
|
|
2019
Q1 | $27.4M | Buy |
66,849
+44,649
| +201% | +$18.4M | 0.08% | 187 |
|
|
2018
Q4 | $8.29M | Sell |
22,200
-344
| -2% | -$126K | 0.1% | 184 |
|
|
2018
Q3 | $9.11M | Sell |
22,544
-224
| -1% | -$85.3K | 0.09% | 193 |
|
|
2018
Q2 | $7.86M | Sell |
22,768
-472
| -2% | -$148K | 0.09% | 189 |
|
|
2018
Q1 | $8M | Sell |
23,240
-596
| -3% | -$207K | 0.09% | 196 |
|
|
2017
Q4 | $8.96M | Buy |
+23,836
| New | +$9.65M | 0.1% | 181 |
|
Other funds holding REGN
MetLife Investment Management's REGN Position: Q2 2026 in Review
MetLife Investment Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.9% in Q2 2026, selling an estimated $468K and leaving 22,880 shares worth $14.3M. The position accounts for 0.06% of the portfolio, ranked #290.
MetLife Investment Management first reported a position in REGN in Q4 2017 and has held it in 35 quarters since. The position peaked at $30.1M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- MetLife Investment Management held 22,880 shares of Regeneron Pharmaceuticals worth $14.3M as of Q2 2026.
- MetLife Investment Management sold 687 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $468K.
- Regeneron Pharmaceuticals made up 0.06% of MetLife Investment Management's portfolio in Q2 2026, its #290 holding.
- MetLife Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Regeneron Pharmaceuticals position peaked at $30.1M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.